Table 3.
Factors that influence median PFS on second line immunotherapy in advanced metastatic melanoma patients.
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| Factor | HR | CI 95% | p-Value | HR | CI 95% | p-Value |
| Age | 1.0 | 0.9–1.0 | 0.6772 | - | ||
| Sex | 0.91 | 0.7–1.2 | 0.5350 | - | ||
| LDH over ULN 2L | 0.57 | 0.4–0.8 | 0.0005 | 0.62 | 0.4–0.9 | 0.0069 |
| ECOG 0 2L | 0.24 | 0.1–0.5 | 0.0004 | 1.51 | 0.5–4.5 | 0.9237 |
| ECOG 1 2L | 0.42 | 0.2–0.8 | 0.4320 | 2.42 | 0.8–6.9 | 0.0179 |
| Brain metastases 2L | 0.58 | 0.4–0.8 | 0.0008 | 0.77 | 0.5–1.1 | 0.1807 |
| Liver metastases 2L | 0.55 | 0.4–0.8 | 0.0002 | 0.66 | 0.5–0.9 | 0.0208 |
| ORR 1L | 0.74 | 0.5–1.0 | 0.054 | 0.84 | 0.6–1.2 | 0.3408 |
| Time to PD 1L > 6 m | 1.49 | 1.1–2.0 | 0.0115 | 1.38 | 1.0–1.9 | 0.0666 |
LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group (performance status); PD, progression disease; ORR (CR + PR), overall response rate; PD, progressive disease; 1L, first line (treatment); 2L, second line (treatment); m, months, HR, hazard ratio; CI confidence interval.